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Intravenous infusion of arrhythmogenic drug solutions was used
as a pharmacological tool to measure the ventricular fibrillation
threshold.
Reserpinized animals increased the fibrillation thresh
old of McN2165.
Animals reserpinized two weeks prior to the e x 
periment still demonstrated an increased fibrillation threshold.
Pronethalol, norepinephine, phenoxybenzamine, and neostigmine all
increased the fibrillation threshold of McN2165, while atropine
produced no change.
Isoproterenol was the only drug that lowered
the threshold.
Reserpinized animals pretreated with norepinephrine
still demonstrated an increased fibrillation threshold.
Isopro
terenol decreased the threshold even when the animals were reser
pinized.
Pronethaloel was able to suspend the fibrillation induced
by McN2165.
Beta receptors appear to be involved in the induction
ventricular fibrillation by McN2165.
Reserpine and pronethalol both increased the fibrillation thresh
old of strophanthin K, while isoproterenol lowered the threshold.
Pronethalol was not able to suspend the fibrillation induced by
strophanthin K.
Reserpine, pronethalol, and isoproterenol all increased the f i 
brillation threshold of barium chloride and pronethalol could not
suspend the fibrillation induced by it.
Normal administration of reserpine and isoproterenol did not
change the threshold of aconitine.
Pronethalol and intraperitoneal injection of reserpine increased the fibrillation threshold.
Pronethalol was also unable to stop the fibrillation induced by
aconitine.
The arrhythmogenic action of McN2165 is different from
any other arrhythmogenic agent used in this study.
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CHAPTER 1
INTRODUCTION
The heart contains four chambers— two thin walled atria
and two thicker-walled ventricles.

The atria lie above the

ventricles and are responsible for forcing the blood they
receive into the ventricles.

The ventricles do most of the

work of the heart, expelling the blood into the circulation.
In the mammalian heart the S.A.

(sino-atrial)

in the right atrium is the pacemaker

node located

(Keith and Flack,

1970).

This region initiates a depolarizing current which spreads
over the atria.
with the A.V.

The atrioventricular or A.V. bundle, begins

(atrioventricular)

node at the base of the

atrial septum and passes along the upper edge of the ven t r i 
cular septum.

The A.V. bundle then divides into two branches

which run down each side of the ventricular septum to the
right and the left ventricles.

Each branch forms a reticu

lated layer under the endocardium of the v e n t r i c l e s , called
Purkinje tissue.

The excitatory process is transmitted

from the S.A. node to the A.V. node and then through the A.V.
bundle to the Purkinje tissue.

The wave of excitation allows

calcium to reach the myofibrils and initiate contraction
(Brody,

1964).

In this way,

the two atria can contract
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almost simultaneously and empty the blood into the two ven
tricles.

The ventricles then contract and expel the blood

into the circulation.
Cardiac output,

the amount of the blood expelled per

heart beat, depends on the heart rate and stroke volume.
Cardiac output is regulated by the autonomic nervous system
and by venous return.

The sympathetic branch of the autonomic

nervous system contains the accelerator fibers that go to the
heart.

Those in the right outflow are distributed mainly to

the S.A. node, and those from the
A.V. node.

left outflow supply the

Stimulation of these accelerator nerves causes

the release of catecholamines, which in turn cause an in
crease in rate
tropism),
cles.

(chronotropism)

and force of contraction

(ino-

This applies both to the atria and to the ven t r i 

Randall

(1956)

showed that the right and left cardiac

sympathetic innervation are different in many respests.

The

right and left stellate ganglia have predominantly chronotro
pic and inotropic effects respectively and the right and left
stellate ganglia have opposite effects on the T wave of the
electrocardiogram

(Yanowitz,

1966).

The other part of the autonomic nervous system is the
parasympathetic nervous system.

The vagus nerves are cardio-

inhibitory, conveying impulses from the cardioinhibitory
center in the medulla to the S.A. node and A.V. node of the
heart.

Both S.A. node and A.V.

autonomic nerves

(Urthaler,

node are influenced by the

et al,

1973).

Stimulation of
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vagus nerve slows the heart rate

(negative chronotropism)

the conductivity of the atria to the ventricles
d r o m o tropism).

and

(negative

Strong stimulation of the vagus can completely

stop the rhythmic contraction of the S.A. node or completely
block the transmission of the cardiac impulse through the A.V.
junction.

The parasympathetic nervous system dominates the

S.A. node while the sympathetic dominates the A.V. node

(Bell,

et a l , 19 7 0) .
Cardiac output is a function of Starling's Law which
states that the force of contraction

(systole)

of the heart

is related to the degree of stretching of the muscle prior
to contraction.

The heart also responds to the blood c o ncen

tration of catecholamines.

These hormones are released by

the adrenal medulla upon stimulation by the autonomic nervous
system.

The central nervous system also plays an important

role in controlling blood pressure and heart rate

(Laubie,

1976).
The S.A. node controls the rate of the heart.

The rate

of depolarization of the S.A. node is considerably greater
than that of any other region of cardiac tissue.
the S.A. node discharges,

Each time

its impulse is conducted both into

the A.V. node and into the Purkinje fibers, discharging their
excitable membranes.
of recovery.

Then all the tissues begin their cycle

But the S.A. node recovers much more rapidly

than does any other part of the heart,
er impulse.

and emits still a n o t h 

Under pathological conditions, other areas of
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the heart develop a rhythmic discharge rate which is more
rapid than that of the S.A. node.

These parts can be the

A.V. node, Purkinje fibers, or any points in the atrial or
ventricular muscle.
ectopic foci.

These additional pacemakers are called

An ectopic pacemaker causes an abnormal se

quence of con t r a c t i o n s .
Abnormal cardiac rhythms can be caused by ;
1.

Abnormal rhythmicity of the pacemaker itself.

2.

Shift of the pacemaker from the S.A. node to other parts
of the heart.

3.

Blocks at different points in the transmission of the
impulse through the heart,

usually from a myocardial

infarction.
4.

Abnormal pathways of impulse transmission through the
heart,

5.

and

Spontaneous generation of abnormal impulses in almost
any part of the heart.
In any general discussion of the

arrhythmias,

the relative merits of the ectopic focus and

reentrant theories,
Segers

initiation of cardiac

{Dawes,

is bound to arise.
1952)

first described the possibility of

an ectopic focus as the origin of arrhythmias.
focus is not limited to one single cell.
group of cells sending rapid impulses

It can be a small

in all directions.

This results in rapid rates of contraction,
tachycardia,

The ectopic

leading to

flutter and even fibrillation.
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The reentrant activity theory consists of two elements;
the circus movement and the focal reexcitation.

McWilliam

(190 8) first described the possibility of circus movement as
the underlying mechanism of cardiac arrhythmias.
to propagation of the impulse in a circular path.

It is due
A funda

mental requirement for such a circus movement is an area of
refractory tissue which initially fails to respond to an im
pulse propagating in one direction.

This is due to the

presence of a unidirectional block.

Because this area then

recovers its excitability,

it accepts reentry of the same

impulse when it returns in the opposite direction.

Such a

continuous circus movement will be possible only if an excit
able area of tissue always exists in front of the excitation
process.

Mauritis and co-workers

(1973) demonstrated the

circus movement as a mechanism of tachycardia in rabbit
atrial muscle preparation.

The other type of reentrant ac

tivity is the focal reexcitation.
a circus movement loop.

It is not associated with

It may occur if there is a disparate

rate of repolarization in neighboring myocardial fibers,

so

that fibers already repolarized are reexcited by fibers still
depolarized.

The potential difference of the depolarized

fibers exceeds the threshold potential of the repolarized
fibers.

This would result in closely coupled ventricular

ectopic beats.

Reexcitation of this type may generate rapid,

repetitive responses in the ventricle.

Han and co-workers

(196 4) demonstrated that focal reexcitation may occur follow
ing coronary occlusion.
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Ventricular fibrillation is a major cause of sudden
deaths from heart diseases.

Evidence indicates that cat

echolamines may be involved in the genesis of the early ven
tricular arrhythmias that accompany an acute myocardial
infarction.

In 1911 Levy showed that epinephrine could

induce ventricular fibrillation in cats under chloroform
anaesthesia.

Raines and co-workers

(1970)

showed that di-

phenylhydantoin increased the fibrillation threshold of
ouabain-induced ventricular arrhythmias by suppression of
the sympathetic influence.

The use of b e t a receptor blocker

seemed to both prevent and cure the fibrillation precipitated
by cardiac glycosides

(Vaughn Williams,

et al,

1963).

It was

found that catecholamines secreted by the sympathetic ganglia
have several biochemical effects on cardiac muscle.

These

hormones stimulate the formation of cyclic 3'5* adenosine
monophosphate by the enzyme adenyl cyclase
et ai,

1961).

(13. W. Sutherland,

The cyclic AMP serves as a "second messenger"

to initiate lipolysis,
cogen synthesis.

glycogenolysis and inhibition of g l y 

High cyclic AMP levels in myocardial muscle

have positive inotropic effects on the heart

(Burthon,

1973).

It has been suggested that catecholamines increase the con
centration of cyclic AMP which in turn acts at the sarco
plasmic reticulum to accelerate the inflow of calcium ions
and cause the positive inotropic effect.

Further studies

showed that cyclic AMP concentration was increased during
ventricular fibrillation caused by ischaemic heart disease
or a myocardial infarction

(Wollenberger et al,

1969).
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Tsien and co-worker

(1972)

found that cyclic AMP in

creased the pacemaker activity in normal Purkinje fibers in
the heart.

This indicated that increases in cyclic AMP

level might lead to repetitive excitation in the partially
depolarized,

ischaemic heart muscle.

Further evidence showed

that the higher cyclic AMP level produced by catecholamines
decreased the ventricular fibrillation threshold in isolated
rat hearts

(Lubbe, et a i , 1976).

It is possible that the

ventricular fibrillation produced by catecholamines is due
to elevated cyclic AMP levels in the myocardial tissue
(Murad, et al,

1961).

There are several techniques employed to study the
mechanism by which an arrhythmogenic drug induces cardiac
arrhythmias.
used

The isolated heart preparation has been widely

(Stafford,

196 3).

Another preparation is the heart-lung

preparation.

This technique was first used by Krayer in 1931

(Burn,

1958).

et al,

The use of the whole animal to measure

the fibrillation dose or fibrillation threshold of barium
chloride was employed by Smith et al,

(1940).

Since then,

intravenous infusion of arrhythmogenic substances to measure
the fibrillation threshold has become one of the classic e x 
periments to measure the efficacy of antiarrhythmic agents.
Also, other drugs were employed in the whole animal prepara
tion to pharmacologically modify the fibrillation threshold.
A disadvantage of this preparation is that a given drug may
have multiple effects on the organism.

The advantage of
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using this preparation in this research is that the nervous
system, hormonal secretion,

and the physiological reflexes

are all present.
Aconitine is a classic arrhythmogenic drug.

Local

application of aconitine to the atrial appendage,

in the

"intact" anesthetized dog produces atrial flutter and fibril
lation

(Sharma,

1963),

Intravenous injection of aconitine

nitrate solution can produce ventricular tachycardia and fi
brillation.

It is believed that these arrhythmias are due

to the rapid discharge of an ectopic focus

(Scherf,

et al,

1949) .
Barium chloride is an inorganic compound that has the
effect of stimulation of all smooth muscles.

Intravenous

injection causes a sharp rise of blood pressure at the same
time as extrasystoles occur.

Barium causes depolarization

and a considerable increase in the after potential.
cient dose can cause ventricular fibrillation

Suffi

(Smith,

et al,

(1940).
Storphanthin K, one of the cardiac glycosides,

has the

ability to increase the force of myocardial contraction.
Cardiac glycosides have been shown to inhibit a sodium and
potassium-stimulated adenosine triphosphatase
sufficiently high dose,
arrhythmias,
et

(ATPase).

cardiac glycosides may precipitate

including ventricular fibrillation

(Sekiya,

a l , 1963).

McN2165 is an experimental compound that can produce
ventricular arrhythmias.

In

It has the effect of increasing
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the QRS interval and cyclic AMP level
Johnson,

1977).

(Pryss,

1969; Eyer and

The terminal effects of the compound in

anesthetized rat included ventricular tachycardia, ventricu
lar flutter, ventricular fibrillation,

and death.

The

mechanism of induction of ventricular fibrillation by this
agent has not been determined.

In order to determine the

role of the autonomic nervous system in the cardiac arrhyth
mias caused by McN2162,

the following autonomic agents were

used ;
Reserpine is an alkaloid found in extracts of R a u w o l f ia
serpentina.

In the central nervous system reserpine depletes

serotonin and norepinephrine from neurons.

Other peripheral

neurons as well as the adrenal medulla are also depleted.
The catecholamine uptake mechanism is also antagonized
et

al,

1958).

(Matti,

Initially, the responses to indirect acting

sympathomimetic amines are potentiated, but later are absent.
The effects of reserpine remain for several weeks.
Neostigmine is an anticholinesterase.

This drug binds

to cholinesterase and is hydrolyzed extremely slowly.

Neo

stigmine has a direct depolarizing action on the neuromuscu
lar junction.

The predominant effects on the heart will be

bradycardia due to enhanced vagus nerve influence on the S.A.
node.
The antagonist to neostigmine is atropine.

Atropine

competitively antagonizes the action of cholinergic drugs
at the muscarinic receptors.

It increases the heart rate by

blocking the effects of vagus nerve on the S.A. node.
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Phenoxybenzamine is a selective a l p h a adrenergic blocker,
totally without effects on the b e t a responses.

It is a very

potent irreversible blocker of norepinephrine.

Therefore,

this drug potentiates the b e t a action of norepinephrine.
Phenoxybenzamine reflexively increases the heart rate because
of its vasodilating action

{Moran, et al,

1962).

Pronethalol is a b e t a adrenergic blocker.

This drug is

a potent blocker of catecholamine action on the heart, and
also has a depressant action on adrenergic nerves,
et

(Standaert,

al, 1967).
Norepinephrine is the postganglionic neurotransmitter

of the sympathetic nervous system.
alpha

It is more active on

receptors than on b e t a receptors, but is by no means

devoid of b e t a activity.
and blood pressure.

Norepinephrine increases heart rate

A sufficiently high dose can cause car

diac arrhythmias.
The actions of isoproterenol are exerted almost entirely
on the b e t a receptors.

This drug produces strong positive

intropic and chronotropic actions on the heart.

Isoproter

enol stimulates adenyl cyclase and is about ten times as
potent as either epinephrine or 1-norepinephrine
et

(Sutherland,

al, 1960).
The effects of these autonomic agents on the arrhythmogenic

action of McN2165 was also compared with their action on the
other arrhythmogenic agents.
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CHAPTER 2
MATERIALS AND METHODS
Methods
Male Sprague-Dawley rats
all the experiments.
pentobarbital

(350-400 grams) were used for

Animals were anesthetized with sodim

(30-35 mg/kg i.p.), supplemented by additional

doses as needed.

The rats were connected to a physiograph

from Narco Bio Systems,

Inc.

The lead II electrocardiograms

(EKG) were recorded continuously with an ink-writing Oscillo
graph

(paper speed 5 cm/sec)

Dual-Beam Oscilloscope.

and monitored on a type 502

McN216 5, aconitine, barium chloride,

and strophanthin K were administered through the femoral vein
by means of an infusion syringe pump
ments)

(Model 255-2 Sage Instru

until ventricular fibrillation occurred.

The rate on

constant infusion of the arrhythmogenic agents was 1.80 mg/
kg/min for McN2165,

4.32 mg/kg/min for barium chloride,

mg/kg/min for aconitine nitrate,
phanthin K.

0,014

and 2.7 mg/kg/min for stro

The infusion was discontinued as soon as the

ventricular fibrillation started,

A timer was used to time

the onset of ventricular fibrillation.
A separate series of experiments,

the animals were in

fused to the point of ventricular fibrillation by the
11
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arrhythmogenic agents.
brillate,

As soon as the heart started to fi-

pronethalol 5 mg/kg was given intravenously to see

if the fibrillation could be suspended.
Preparation and Administration of Drugs
These arrhythmogenic agents are prepared as follows :
Because of its low water solubility, McN216 5 (McNeil
Laboratories,

Inc.) was dissolved in 75% alcohol and 25%

normal saline.

This drug was agitated approximately 15 m i n 

utes until it all dissolved, yielding a solution of 10 m g / m l .
Aconitine nitrate

(S. B. Penick and Company),

(J. T. Baker Chemical Co.), and strophanthin K
Biochemical Corporation)

barium chloride
(Nutritional

were dissolved in distilled water to

give a solution of 0.5 m g / m l , 40 mg/ml,

and 25 mg/ml respec

tively.
Proenthalol

(Ayerst Laboratories)

(Hoffmann-LaRoche, Inc.)

neostigmine bromide

and atropine sulfate

(Mallinckrodt

Chemical Works) were dissolved in distilled water and ad m i n 
istered rapidly via the femoral vein ten minutes prior to
infusion of the arrhythmogenic agent.
L-Isoproterenol-D-Bitartrate
norepinephrine

(Sigma Chemical Co.)

and

(Levophed^ Bitartrate, Winthrop Laboratories,

Inc.) were dissolved in distilled water and were given intra
venously twenty seconds prior to the arrhythmogenic agents.
Phenoxybenzamine hydrochloride

(Smith Kline and French

Labs.) was dissolved in distilled water and given intraperitoneally one hour before infusion.

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

13
Reserpine

(Serpasi^,

CIBA pharmaceutical Co,) was d i s 

solved in distilled water at pH 2.2 by addition of acetic
acid.

This drug was given to three groups of animals intra

muscularly at 1.2 5 mg/kg 72 hours prior,

2.5 mg/kg 24 hours

prior and 2.5 mg/kg 2 weeks prior to infusion in the McN2165
experiment.

In the barium chloride,

nitine experiments,

strophanthin K and a c o 

the rats were injected with 2.5 mg/kg of

reserpine intramuscularly 24 hours prior to infusion-

In the

aconitine experiment, one group of rats was given 2.5 mg/kg
of reserpine intraperitoneally 24 hours prior to infusion.
Calculations
The heart rates of the animals were recorded before p r e 
treatment to see if the pretreatment had any effect on
cardiac rhythm.

The time required for the arrhythmogenic

agents to induce ventricular fibrillation was converted to
dose.
(sec)

The following formula was used to convert the time
to dose

(mg/kg):

time (sec) x Concentration of drug (mg/ml)
_________ X rate of infusion (ml/sec)________
weight (kg)
The total doses were averaged to give a mean dose plus or
minus the standard deviation.
The doses required to produce these changes were co m 
pared for the control and drug-treated groups.

Student's

t-test was used for statistical analysis of the result.
5% level of significance was arbitrarily chosen to define
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whether values were or were not significantly different.
The fraction of fibrillating animals was also calculated and
recorded.
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CHAPTER 3
RESULTS AND DISCUSSION
Preliminary Findings
Anesthetized rats were hooked up to the Lead II elec
trocardiograph for observation.

It was found that the dose

of sodium pentobarbital that was just sufficient to anes
thetize the animal had little or no suppressant effect on the
heart.

The average heart rate was 420 beats per minute.

There was uniform heart rhythm and no arrhythmias or abnormal
beats were found in any anesthetized rats.
Kostis and co-worker

(1973)

showed that alcohol demon

strated antiarrhythmic properties at high doses and also
suppressed ventricular tachycardia.

The ventricular fibril

lation threshold was increased as the blood alcohol concen
tration increased and the threshold value decreased as the
alcohol level decreased with time.

In the present s t u d y ,

control solution of 75% alcohol and 25% saline was infused
into ten of the anesthetized animals.

The heart rate did not

change after infusion of 0.5 ml and a slight decrease in
heart rate to about 380 beats per minute occurred after 1.5
ml of infusion.

These volumes are above the average volume

15
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(0.3 - 0.4 ml) of infusion of McN2165 used to induce ventri
cular fibrillation.
The effects of norepinephrine and isoproterenol on
reserpinized animals was investigated-

A dose of 4 yg/kg of

norepinephrine was the highest dose that could be given w i t h 
out causing any cardiac arrhythmias.

The maximum dose of

isoproterenol was also in the same dosage range.
A dose of 2.5 mg/kg

(IM) reserpine was given to the

animals for the reserpinized experiment.

The animals were

sedated and exhibited some diuretic effects after 24 hours.
The animals given intraperitoneal reserpine also appeared to
have a lower body temperature.
Animals pretreated with atropine showed a mild increase
in heart rate which meant the vagal influence was blocked.
Likewise,

animals pretreated with neostigmine showed decreased

heart rate due to an increased vagal influence.
Animals pretreated with phenoxybenzamine had a higher
heart rate than the control.
agent.

This is a common effect of this

The animals pretreated with pronethalol had a lower

heart rate due to beta, adrenergic blockade.
Results
Effects of reserpine pretreatment on ventricular fibril
lation induced by McN216 5 (Table 1 ).

The reserpinized animals

were sedated and their heart rate was depressed from 42 0/min
to 360/min and 240/min in a dose-related fashion.
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TABLE 1
Effect of reserpine pretreatment on ventricular
fibrillation induced by McW2165

Treatment

Fibrillation
threshold (mg/kg)

Fraction
fibrillating

Control

6.6 + 1.0

20/30

Reserpine 1.25 mg/kg 72 hrs

7.2 + 1.9

7/9

Reserpine 2.5 mg/kg 24 hrs
Reserpine 2.5 mg/kg 2 wks

10. 4 ± 3.5*
8.1 + 1.8*

8/10
9/9

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the
animal to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals
that demonstrated ventricular fibrillation to the total
animals used in the experiment.
*significantly different from control

(p < 0.01)
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ment with reserpine

(.1.25 mg/kg

72 hrs.)

showed an in

significant increase in the fibrillation threshold to 7.2 ±
1.9 mg/kg.

An intramuscular dose of 2.5 mg/kg

(.24 hrs. prior)

of reserpine increased the threshold significnatly to 10.4 ±
3.5 mg/kg

(p < 0.01).

The same dose given two weeks before

infusion raised the threshold to 8.1 ± 1.8 mg/kg

(p < 0.01)

which was still significantly different from the control.
MCN2165 was administered by intravenous infusion to 23
rats.

Twenty out of 2 3 animals produced ventricular fibril

lation after a period of time.

The average threshold dose to

induce ventricular fibrillation was 6.6 ± 1.0 mg/kg.
of the rats never exhibited ventricular fibrillation.

Three
Their

hearts went into tachycardia then slowed to a stop as the
infusion was continued.

The McN2165 induced cardiac arrhyth

mia went gradually from tachycardia to ventricular flutter
and terminated with ventricular fibrillation.
tion lasted about 45 seconds to one m i n u t e .

The fibrilla
After the fi

brillation the heart exhibited cardiac standstill with occ a
sional beats.
Effects of autonomic drugs on ventricular fibrillation
induced by McN2165

(Table 2 ) .

0.05 mg/kg isoproterenol,
to 540/min.

Immediately after injection of

the heart rate went up from 420/min

Isoproterenol decreased the threshold dose from

6.6 ± 1.0 mg/kg to 4.4 ± 0.4 mg/kg

(p < 0.01).

After injection of pronethalol,

the heart rate decreased

to about 300/min and then came back to about 380/min after
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TABLE 2
Effect of autonomic drugs on ventricular
fibrillation induced by McN2165

Treatment

Fibrillation^
threshold (mg/kg)

Fraction^
fibrillation

Control

6. 6 + 1.0

Isoproterenol 0.05 mg/kg

4.4

Pronethalol 2 mg/kg

7.3 + 1.6

9/12

Pronethalol 5 mg/kg

7.5 ± 1.0#

9/15

Norepinephrine 4 pg/kg

7.5 ± 1.2#

9/9

Phenoxybenzamine 1 mg/kg

8.1 ± 1.7*

11/11

Neostigmine 0.1 mg/kg

8.3

Atropine 1 mg/kg

6.4 + 0.8

4*

0.4*

2.7#

20/23
10/10

6/9
6/6

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the
animal to cause ventricular fibrillation.
b

Fraction f i l b r i H a t i n g is defined as the ratio of the
animals that demonstrated ventricular fibrillation to the
total animals used in the experiment.

*significantly different from control

(p < 0.01)

#significantly different from control

(0.02 < p < 0,05)
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10 minutes.

Pronethalol at a dose of 2 mg/kg increased the

threshold slightly but not significantly.

Five mg/kg of p r o 

nethalol increased the fibrillation threshold to 7.5 ± 1.0
mg/kg

(0.02 < p < 0.05).
Phenoxybenzamine 1 mg/kg increased the heart rate to

500/min.

The fibrillation threshold was also increased to

8.1 ± 1.7 mg/kg

Cp < 0.01).

The increased heart rate may be

due to reflex vasodilation or potentiation of the effect of
catecholamines on heart rate.
phenoxybenzamine

(Stafford,

This is a common effect with

1963),

A dose of 4 wg/kg of norepinephrine and 0.1 mg/kg of
neostigmine increased the fibrillation threshold to 7.5 ±
1.2 mg/kg
0.05)

(0.02 < p < 0.05)

and 8.3 ± 2.7 mg/kg

(0.02 < p <

respectively.
There was a slight increase in heart rate after 1 mg/kg

of atropine but there was no change in the fibrillation
threshold.
blockage

The increased heart rate may be due to vagal

(Goodman and Gilman,

19 70),

Effects of reserpine pretreatment and autonomic drugs
on ventricular fibrillation induced by McN2165

(Table 3 ) .

Pretreatment w ith reserpine

(2.5 mg/kg IM, 24 hrs.)

norepinephrine

20 sec.)

raised

(4 yg/kg IV,

before McN2165 infusion

the threshold to 10.5 ± 2.1 mg/kg

pretreatment with 2.5 mg/kg of reserpine
0.05 mg/kg of isoproteronol
threshold to 4.5 ± 0.7 mg/kg

and

(IV, 20 sec.)
(p < 0.01),

(p < 0.01) .
(IM 24 hrs.)

VJhile
plus

decreased the
These data imply
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TABLE 3
Effect of reserpine pretreatment and autonomic
drugs on ventricular fibillation induced by McN2165

Treatment
Control

Fibrillation^
threshold (mg/kg)

Fraction^
fibrillating

6.6 ± 1.0

20/23

Reserpine 2,5 mg/kg 24 hrs

10.4 ± 3.5*

8/10

Reserpine 2.5 mg/kg 24 hrs
+ norepinephrine 4 yg/kg

10.5 ± 2.1*

8/11

Reserpine 2.5 mg/kg 24 hrs
+ isoproterenol 0,05 mg/kg

4.5 ± 0.7*

10/10

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the
animal to cause ventricular fibrillation.
^Fraction f i b r i H a t i n g is defined as the ratio of the
animals that demonstrated ventricular fibrillation to the
total animals used in the experiment.
*significantly different from control

(p < 0.01)
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the involvement of the autonomic nervous system in the
M c N 2 165-induced arrhythmias.
Effects of reserpine pretreatment on ventricular fibril
lation Induced by various arrhythmogenic agents

(Table 4 ).

Strophanthin K induced ventricular fibrillation at 25.4 ±
2.4 mg/kg.

Initially, the heart rate was decreased.

This

was followed by some disturbances of the QRS complex.

Further

infusion caused ventricular fibrillation and cardiac arrest.
Pretreatment with 2.5 mg/kg reserpine
the threshold to 33.5 ± 3.5 mg/kg

(IM, 24 hrs.)

increased

Cp < 0.01).

Barium chloride induced ventricular fibrillation at 21.7
± 4.0 mg/kg.

The heart went through tachycardia for a brief

period followed by a sudden onset of ventricular fibrilla
tion.

Cardiac standstill occurred in about 30 seconds.

Re-

serpinization raised the threshold dose approximatly 50%.
Aconitine induced ventricular fibrillation at 0.043 ±
0.01 mg/kg.

This agent caused ventricular tachycardia and

ventricular fibrillation within a short period of time.
treatment with reserpine at a dose of 2.5 mg/kg
did not change the threshold.
kg 2 4 hrs.)

Pre

(IM, 24 hrs.)

The same pretreatment

(2.5 mg/

given intraperitoneally raised the threshold to

0.093 ± 0.03 mg/kg

(p < 0.01), which is a 110% increase.

Effect of pronethalol pretreatment (5 mg/kg IV, 10 min.)
on ventricular fibrillation induced by various arrhythmogenic
agents

(Table 5).

A dose of 5 mg/kg of pronethalol increased
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TABLE 4
Effect of reserpine on ventricular fibrillation
induced by various arrhythmogenic agents

Treatment

Fibrillation^
threshold (mg/kg)

Fraction^
fibrillating

Strophanthin K

25. 4

2.4

7/7

Strophanthin K +
Reserpine 25 mg/kg 24 hrs

33,5

3,5*

7/7

Barium chloride

21. 7

4.0

9/9

Barium chloride +
Reserpine 2.5 mg/kg 24 hrs

33.7

4.3*

11/11

Aconitine

0.043

0.01

10/10

Aconitine +
Reserpine 2.5 mg/kg 24 hrs

0.053

0.02

6/6

Aconitine +
Reserpine 2.5 mg/kg IP 24 hrs

0.093

0.03*

9/9

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the
animal to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals
that demonstrated ventricular fibrillation to the total
animals used in the experiment.
*significantly different from control

(p < 0.01)
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TABLE 5
Effect of pronethalol on ventricular fibrillation
induced by various arrhythmogenic agents

Treatment

Fibrillation^
threshold (mg/kg)

Fraction^
fibrillating

Strophanthin K

25. 4

± 2.5

7/7

Strophanthin K -f
Proethalol 5 mg/kg

36.4

± 6.4*

4/10

Barium chloride

21.7

+ 4.0

9/9

Barium chloride +
Pronethalol 5 mg/kg

38.5

± 8.0*

8/8

Aconitine

0. 042 ± 0. 01

Aconitine +
Pronethalol 5 mg/kg

0. 055 ± 0.01#

10/10
7/7

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the animal
to casue ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals
that demonstrated ventricular fibrillation to the total
animals used in the experiment.
*significantly different from control

(p < O.Ol)

^significantly different from control

(.0.02 < p < 0.05)
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the fibrillation threshold significantly for all three arrhy
thmogenic agents.

The threshold dose for strophanthin K,

barium chloride and aconitine after pretreatment with 5 mg/
kg of pronethalol
0.01),

(IV, 10 min.) were 36.4 ± 6.4 mg/kg

35.5 ± 8.0 mg/kg

(.0.02 < p < 0.05)

(p < 0.01)

and 0.055 ± 0.01 mg/kg

respectively.

Effect of isoproterenol pretreatment
sec.)

(0,05 mg/kg IV, 20

on ventricular fibrillation induced by various arrhyth

mogenic agents

(Table 6 ) .

Isoproterenol decreased the fibril

lation threshold of strophanthin K to 15.7 ± 4.2 mg/kg
0.01)

(p <

(p <

and increased the fibrillation threshold of barium

chloride to 31.9 ± 4.3 mg/kg

(p < 0.01).

The fibrillation

threshold of aconitine was not significantly altered by iso
proterenol pretreatment.
Effect of pronethalol 5 mg/kg on cessation of ventricu
lar fibrillation
of pronethalol,

(Table 7 ) .

A intravenous dose of 5 mg/kg

given at the onset of ventricular fibrillation

induced by McN216 5, restored the normal rhythm in 11 out of
11 animals.

None of the eight animals stopped ventricular

fibrillation after induction by barium chloride.

Also, no

aconitine-induced fibrillation could be halted with 5 mg/kg
of pronethalol.
Discussion
The production of ventricular arrhythmias by McN2165 in
anesthetized dogs was first published by Pruss

(1969).
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TABLE 6
Effect of isoproterenol on ventricular fibrillation
induced by various arrhythmogenic agents

Treatment

Fibrillation^
threshold (mg/kg)

Fraction^
fibrillating

Strophanthin K

25.4

2.5

7/7

Strophanthin K +
Isoproterenol 0.05 mg/kg

15,7

4.2*

3/8

Barium chloride

21,7

4.0

9/9

Barium chloride +
Isoproterenol 0.05 mg/kg

31. 9

4.3*

8/8

Aconitine

0.042

0,01

10/10

Aconitine +
Isoproterenol 0.05 mg/kg

0.051

0.01

8/8

Fibrillation threshold is defined as the total dose (mg/kg)
of the arrhythmogenic agent that was infused into the animal
to cause ventricular fibrillation.
^Fraction fibrillating is defined as the ratio of the animals
that demonstrated ventricular fibrillation to the total
animals used in the experiment.
*significantly different from control

(p < 0.01)
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TABLE 7
Effect of 5 mg/kg of pronethalol on recovery
from ventricular fibrillation

Treatment
MCN2165
MCN2165 + Pronethalol

Fraction Recovery^
0/20
11/11

Barium chloride

0/9

Barium chloride + Pronethalol

0/8

Aconitine

0/10

Aconitine + Pronethalol

0/8

^Animals were given sufficient arrhythmogenic agent
to induce fibrillation.
At this point, 5 mg/kg of
pronethalol was given.
Fraction recovery is the
ratio of those who returned to normal rhythm to the
total number that fibrillated

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

28
Further studies by Eyer and Johnson

(1977)

showed that MCN2165

slowed the heart rate and increased the cyclic AMP level in
isolated fetal rat heart preparations.

The same study also

found that McN216 5 could not induce tachycardia or ve ntricu
lar fibrillation in such a preparation.

One possible explan

ation could be that the fetal rat did not have a well d e v e l 
oped sympathetic nervous system.

Since sympathetic activity

might be involved, reserpine was used to determine the rela
tionship between catecholamines and fibrillation.
has a biphasic effect on the heart rate
After reserpine administration,

This drug

(Krayer, et al,

1958).

the heart rate increased for

the first few hours due to the release of catecholamines,
then decreased for about two to three weeks due to the dep le
tion of these amines.

About four weeks was required for the

animals to return to normal levels of catecholamines.

Direct

cardiac effects of reserpine include depression of excitable
membranes

(Innes,

et

al,

1958).

The ability of reserpine to

increase the fibrillation threshold was most likely due to
the depletion of catecholamines.

In this study the antifi-

brillatory action persisted for more than four weeks.

The

possibility of a direct membrane effect of reserpine can be
ruled out because the antifibrillatory action persisted long
after the drug had been excreted.

A 1.2 5 mg/kg dose of r e 

serpine caused less sedation than a dose of 2.5 mg/kg and did
not significantly raise the fibrillation threshold

(Table 1).

This was probably due to less depletion of the catecholamines.
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The 2.5 mg/kg dose

(24 hrs prior) was a sufficient dose to

deplete all the catecholamines without much membrane effect
(Boyajy,

et

al,

1965).

Therefore,

the increase in ventricu

lar fibrillation threshold by reserpine implied that catecho
lamines might play a role in the fibrillatory action of
MCN2165.
A dose of 0.1 mg/kg of neostigmine increased the fibril
lation threshold significantly while atropine did not change
the threshold.

Large doses of acetylcholine are known to

convert the atrial flutter induced by aconitine into fibril
lation through the development of multiple re-entries in the
atria

(Sharma,

1963;

Burn,

et

a l , 1956),

It was also found

that acetylcholine or carbachol was able to inhibit the syn
thesis of cyclic AMP by 20 to 30% in dog cardiac muscle
preparation

(Murad,

et

al,

1961).

This increase in threshold

by neostigmine can be explained if M c N 2 165-induced fibrilla
tion requires increased cyclic AMP levels,
shown to elevate cyclic AMP levels

McN2165 has been

(Eyer and Johnson,

1977).

The lack of effect of atropine on M c N 216 5 was in agreement
with Pruss'

(1969)

finding.

Blockade of the a l p h a and b e t a

receptors by 1 mg/kg of

phenoxybenzamine and 2 mg/kg or 5 mg/kg of pronethalol in
creased the fibrillation threshold.
alpha

and b e t a

fibrillation.

This implied that both

receptors were involved in the induction of
Only 9 out of 15 rats pretreated with p r o 

nethalol fibrillated.

The other six animals demonstrated no
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arrhythmias whatsoever.

All the animals pretreated with

pnehoxybenzamine underwent ventricular fibrillation.

This

indicated the involvement of b e t a receptors in the arrhyth
mias induced by McN2165,
on both a l p h a

and b e t a

although the agent might have acted

receptors.

Pronethalol itself had

some transient cardiac depressant actions similar to quinidine
(Sekiya,

et

al,

1963).

It is also known that b e t a receptor

blockers are effective in preventing the beta-stimulated
elevation of cyclic AMP levels in the cardiac tissue
et

(Dobson,

a 1 , 1973) .

The norepinephrine data was difficult to explain because
it increased the fibrillation threshold

(Table 2).

This

could be due to the biphasic effects catecholamines have on
the fibrillation threshold-

In low doses,

catecholamines

increased the ventricular fibrillation threshold and in high
doses it lowered the threshold
Hoffman,

et

al,

1955).

(MacConaill,

et

a l , 1967,

Evidently the high dose that lowered

the threshold was not attained.

Another explanation could be

that norepinephrine acted more on the a l p h a receptors than
the b e t a receptors.

Alpha

receptor activation may be related

to decrease in the intracellular level of cyclic AMP
et

al,

creased

1967).

Isoproterenol,

a potent b e t a

the fibrillation threshold

(Turtle,

agonist, d e 

(Table 2).

Beta

agonists

also effectively increase cyclic AMP levels in the heart
(Sutherland, e t al,

1960),

In reserpinized animals,

isopro

terenol was capable of lowering the fibrillation threshold.
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This was not possible with norepinephrine.

This was further

evidence that b e t a receptors are more involved than a l p h a
receptors in the arrhythmogenesis produced by McN2165.
McN2165 has been shown to slow conduction of the action
potential in

the heart, block the A.V. node

and increase

the cyclic AMP level (Eyer and

(_Pruss, 1969),
Johnson,

1977).

High cyclic AMP levels have been implicated in ventricular
fibrillation

(Opie,

et al,

1976),

Neostigmine and pro net h

alol, agents that lower the cyclic AMP levels in the heart,
increased the McN2165 fibrillation threshold.

Isoproterenol

increased the level of cyclic AMP and decreased this thresh
old.

Only isoroterenol could decrease the fibrillation

threshold of

reserpinized animals to the control value.

elevation of

cyclic AMP levels in the heart

Thus,

are implicated in

the fibrillatory response to McN2165.
Of the three arrhythmogenic agents compared with McN2165,
only strophanthin K and barium chloride elevated the fibril
lation threshold in reserpinized animals
prior to t rea tm e n t ) .

Tatsuno

(1976)

(2.5 mg/kg 24 hrs

also found that sympa

thetic activities were involved in the production of arr hy
thmias by strophanthin K,

Blockage of strophanthin K-

induced arrhythmias by a i>eta-adrenergic antagonist is well
documented
1963).

(Somani and Lum,

1965;

Sekiya and Vaughan Williams,

Lowered fibrillation threshold following isoproterenol

pretreatment further demonstrated that b e t a

sympathetic acti

vities are involved in the induction of ventricular fibrilla
tion .

Reproduced with permission of the copyright owner. Further reproduction prohibited without permission.

32
Pretreatment with reserpine, pronethalol and isoproter
enol all increased the fibrillation threshold of barium
chloride.

Barium chloride causes arrhythmias by direct m y o 

cardial irritation.

It resembles calcium in its ability to

produce extrasystoles,

increase cardiac automaticity and in

duce ventricular fibrillation

(McMillan,

et a l , 1928).

It

is possible that the slight membrane effect of reserpine or
pronethalol was able to suppress the irritation of barium
chloride,

so that it took more barium chloride to irritate

the myocardial muscle, while isoproterenol increased the
heart rate and force which made it more difficult for barium
chloride to disturb the increased rhythm.
A dose of 2.5 mg/kg of reserpine

(IM 24 hrs. prior)

not alter the fibrillation threshold of aconitine.

did

The same

dose given intraperitoneally increased the threshold signi
ficantly.

This showed that either catecholamines may not be

involved in the arrhythmia or only a low level of catechol
amines is necessary for aconitine-induced fibrillation.

The

increase in threshold might be due to the enhanced membrane
activity of reserpine because intraperitonea1 injection pro 
duced higher blood levels of the drug

(Goldstein,

1974).

Another explanation could be that a minute amount of c a t e 
cholamines is required for aconitine to induce fibrillation.
With a higher blood concentration of reserpine,

there will be

a greater depletion of catecholamines, which could increase
the amount of aconitine required to induce fibrillation.
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Isoproterenol pretreatment did not change that threshold.
This is further evidence that catecholamines were not in
volved in the arrhythmias or that only small amounts are
needed.

Pronethalol increased the aconitine fibrillation

threshold,

contrary to the data of Tatsuno,

et ai, (1976),

The quinidine-like or local anesthetic effect is unlikely
because administration of pronethalol failed to suspend the
fibrillation induced by aconitine.

Pronethalol could have

some other unknown effects on suppressions of ectopic activ
ities of aconitine.
A dose of 5 mg/kg of pronethalol was injected intraven
ously during the ventricular fibrillation induced by McN2165,
barium chloride,

and aconitine

(Table 7).

induced fibrillation was suspended.
to normal rhythm.

Only McN2165-

These hearts returned

Barium chloride-and aconitine-induced fi

brillation were not suspended by pronethalol.

The fibrilla

tion continued until cardiac arrest occurred.
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CHAPTER 4
SUMMARY
McN2165 is an arrhythmogenic agent that produces v e n 
tricular fibrillation in rats.

In order to investigate the

mechanism of action of this agent,

autonomic agonists and

antagonists were employed to modify the physiological states
of the rat heart.

The influence of these autonomic drugs on

McN2165-induced ventricular fibrillation was compared with
other arrhythmogenic agents.

Pretreatment with either

reserpine, pronethalol, norepinephrine, phenoxybenzamine or
neostigmine increased the fibrillation threshold of McN2165.
Atropine pretreatment did not change the fibrillation
threshold, while isoproterenol pretreatment decreased the
fibrillation threshold.

Norepinephrine failed to decrease

the fibrillation threshold of the reserpinized animals.

Iso

proterenol was the only autonomic drug that could decrease
the McN2165 fibrillation threshold in the reserpinized
animals.

When fibrillation was induced by M c N 2 1 6 5 , ad minis

tration of pronethalol restored normal cardiac rhythm.
The fibrillation threshold of strophenthin K was in
creased by either reserpine or pronethalol pretreatment.
Isoproterenol was able to lower the fibrillation threshold
34
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but pronethalol was not able to stop the fibrillation induced
by the agent.
Pretreatment with either reserpine, pronethalol or
isoproterenol raised the fibrillation threshold of barium
chloride,

Pronethalol was not able to stop the fibrillation

induced by barium chloride.
Intraperitoneal injection of reserpine and pretreatment
with pronethalol increased the fibrillation threshold of
aconitine.

Isoproterenol did not change the fibrillation

threshold of aconitine.

Aconitine-induced ventricular fibril

lation could not be halted by pronethalol.
These data demonstrate a stronger involvement of the
beta

receptor in the action of McN2165 than for the other

arrhythmogenic agents studied.

Although these agents re 

sembled MCN2165 in some respects, certain differences in
their mechanism of action have been d e m o n str ate d-
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